CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomized superiority trial Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock Select Drug-Drug Interactions With Direct Oral Anticoagulants An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation The mSToPS Randomized Clinical Trial Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study

Editorial2017 Dec 12;70(23):2875-2877.

JOURNAL:J Am Coll Cardiol. Article Link

Can the Vanishing Stent Reappear? Fix the Technique, or Fix the Device?

King SB 3rd, Gogas BD. Keywords: bioresorbable vascular scaffold; prognosis; randomized trial; stent; technique; thrombosis

FULL TEXT PDF